Intellectual Property - March 12, 2020
Cantargia acquires Cellerant IP on IL1RAP
Cantargia has announced the acquisition of a patent portfolio from Cellerant Therapeutics Inc covering aspects around the interleukin 1 receptor accessory protein (IL1RAP). The acquired IP includes a US patent on IL1RAP as a target for antibody therapy in leukemia. Thereby, Cantargia has broadened its IP portfolio and secured ownership of the key patents around […]
Financing - February 20, 2020
Cantargia completes a directed share issue of approximately 410 million SEK
Through the Directed Share Issue, Cantargia will receive proceeds amounting to approximately SEK 410 million before transaction related costs. Investors in the Directed Share Issue are a wide range of Swedish and international investors including new investors such as Swedbank Robur, HBM Healthcare Investments, Granite Point Capital and Unionen as well as current shareholders such […]
Clinical Trials - December 12, 2019
Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis
Cantargia has announced that its research platform CANxx has progressed with the start of a drug development project, CAN10. The project originates from inhibition of three inflammatory cytokine systems (IL-1, IL-33 and IL-36) by antibody targeting of interleukin 1 receptor accessory protein (IL1RAP). The project will focus on unmet medical need in systemic sclerosis and […]
Intellectual Property - October 16, 2019
An opposition has been filed against one of Cantargia’s patents
An opposition has been filed against one of the European patents in Cantargia’s patent family covering antibody therapy in solid tumors. The patent confers protection for e.g. IL1RAP targeted antibodies in tumor forms not already covered in the European mother patent, which was granted in 2016. The current opponent, Mab Discovery GmbH, also filed an […]
Pharma Business - October 6, 2019
Cantargia submits request for pre-IND meeting
The company announced last month that a request for a pre-IND meeting with the US FDA has been submitted. The purpose of the meeting is to discuss the current documentation on the antibody CAN04 and a proposed new phase I clinical combination study with CAN04 and an immune checkpoint inhibitor under a US IND. The […]
Clinical Trials - August 26, 2019
Positive preclinical data from Cantargia
The company has announced new positive preclinical data which defines a novel additional development opportunity for Cantargias antibody CAN04. The molecular target for CAN04, IL1RAP, has been detected on the cancer cells in approximately 80 % of patients with bladder cancer. Furthermore, a pronounced and statistically significant single agent activity was documented in an in […]
